Overview

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Status:
Recruiting
Trial end date:
2023-04-19
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control adenoid cystic cancer that has a NOTCH pathway activation.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center